Soligenix Inc. (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, with particular focus on advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma. The company expects interim analysis in the second quarter of 2026 and top-line results in the second half of the year, marking significant milestones in the development of this novel photodynamic therapy.
The company also noted regulatory momentum with orphan drug designation for dusquetide in Behçet's Disease, a rare inflammatory disorder. This designation provides potential benefits including market exclusivity and development incentives, supporting Soligenix's ongoing development of SGX302 and SGX945 programs. The company reported a year-end cash position of approximately $7.9 million as it continues to pursue strategic options to support late-stage development.
Soligenix's Specialized BioTherapeutics business segment is developing HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, and the first-in-class innate defense regulator technology, dusquetide (SGX942) for the treatment of inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 in Behçet's Disease.
The Public Health Solutions business segment includes development programs for RiVax(R), the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax(TM), the vaccine candidate for the prevention of COVID-19. The development of these vaccine programs incorporates the proprietary heat stabilization platform technology known as ThermoVax(R). This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
The progress reported by Soligenix has implications for patients with rare diseases who currently face limited treatment options. The advancement of the Phase 3 FLASH2 trial represents potential new therapeutic approaches for cutaneous T-cell lymphoma patients, while the orphan drug designation for dusquetide in Behçet's Disease addresses significant unmet medical needs in inflammatory conditions. For the biotechnology industry, Soligenix's progress demonstrates the viability of developing treatments for rare diseases through strategic pipeline management and regulatory pathway navigation.
The company's latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. BioMedWire, which distributed the press release, is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors, and is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions. For more information about BioMedWire, please visit https://www.BioMedWire.com. Full terms of use and disclaimers applicable to all content provided by BMW are available at https://www.BioMedWire.com/Disclaimer.
